Medical device company CoNextions Inc reported on Monday the receipt of US FDA 510(k) clearance for CoNextions TR Tendon Repair System for soft-tissue repair leading to improved patient outcomes.
With expected availability in May 2022, the novel CoNextions TR Tendon Repair system addresses traumatic tendon lacerations in the hand, wrist and forearm, the company added.
The company is encouraged with the outcome of the US FDA review of its 510(k) submission supported by 90% patient clinical trial and are excited about the upcoming introduction and commercial launch of the product, its president and CEO Jeffrey Barnes stated.
CoNextions TR enables a stronger, faster and smoother repair of tendon lacerations. A prospective randomized clinical trial also showed a lower rate of treatment failure and rupture compared to conventional suture repairs. The CoNextions TR device is another example of CoNextions' commitment to providing innovative and advanced solutions, added EVP of Sales and Marketing, Dan Gruppo.
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon
Enable Injections names new chief operating officer
BridgeBio Pharma and Kyowa Kirin partner on infigratinib for skeletal dysplasias in Japan
Redwood Scientific signs agreement with Jeeva Clinical Trials
Tissue Regenix ships first allograft products in the EU post-HPRA approval
Kromek secures GBP1.3m grant for AI-powered radiation sensor project